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ABSTRACT 
Objectives: Ovarian cancer remains a very common cause of death among women 
worldwide. The cause is to be found in too late of a diagnostic process and therapeutic 
difficulties The presence of heat shock proteins in the serum of ovarian cancer patients is still 
a new area of study. It is necessary to continue studies on the possibilities for using these 
markers to predict a patient’s response to a specific therapy and to monitor treatment progress. 
Material and methods: The study included 52 women with ovarian cancer, hospitalised at 
the Department of Obstetrics, Gynaecology and Oncological Gynaecology, Medical 
University of Silesia. The control group consisted of 25 healthy women. The levels of HSP27 
in the studied sera were determined by an immunoenzymatic method (ELISA). 
Results: The mean concentration of HSP27 in the group of patients with ovarian cancer was 
significantly higher than in the control group of healthy women. We have shown that mean 
HSP27 levels in ovarian cancer patients increase with tumour progression and further depend 
on the clinical stage of the disease (FIGO). Positivity values analysis revealed in all clinical 
stages of ovarian cancer, excluding stage 1, it was significantly higher than in the control 
group, and at the 4th stage, it is significantly higher than at the 1st, 2nd, and 3rd stages. 
However, both for the untreated patients and those patients after chemotherapy, the mean 
HSP27 levels were significantly higher than in the control group. 
Conclusions: Our studies indicate a significant contribution of HSP27 to the pathogenesis of 
ovarian cancer. It seems that serum HSP27 can be a marker for this cancer’s development, 
and a marker for the clinical stage. 
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INTRODUCTION 
Ovarian cancer remains a very common cause of death among women worldwide. The 
cause is to be found in too late of a diagnostic process and therapeutic difficulties [1]. Most 
women diagnosed with high stage ovarian cancer respond well to primary chemotherapy, but 
they usually succumb to a chemoresistant recurrence within two years [2]. Key to a significant 
improvement in ovarian cancer treatment results and prognoses is, therefore, finding efficient 
methods for the early diagnosis of this cancer and better understanding of the mechanisms 
responsible for drug resistance to standard chemotherapy. During ovarian carcinoma, an 
important role is played by the immune response directed against neoplastic cells, especially 
apoptosis. It is one of the key processes leading to the initiation of carcinogenesis [3]. 
 Recently, an important role of heat shock proteins (HSPs) in the formation of 
malignant processes, including those within the ovary, has been found. This role mainly 
includes facilitating tumour transformation, increasing cancer cell survival and affecting 
anticancer drug resistance [4, 5]. One of the heat shock proteins strongly associated with 
carcinogenesis is HSP27. In addition to its role as a chaperone protein, it is also responsible 
for balancing the intracellular redox effect, cytoskeleton stabilisation and control of the 
internal cell differentiation and proliferation processes, as well as apoptosis and neoplastic 
transformation [6]. There is evidence that HSP27 protects cells from apoptosis-inducing 
stressors such as cytokines, ionizing radiation and oxidative stress [7]. Thus, on one hand, this 
protein protects a correct cell against the harmful effects of hypoxia or toxic physical and 
chemical agents. On the other, increased HSP27 activity induced by prolonged cellular stress 
may lead to inhibition of apoptosis, facilitating cell neoplastic transformation [8]. 
Furthermore, HSP27 may then protect transformed cancer cells from renaturing their cellular 
proteins which have been destroyed by cytostatic drugs used in treatment of cancer, which 
contributes to their increased malignancy and non-response to the drugs used [9].  
Although, typically, heat shock proteins are located intracellularly, it is known that 
they can also be released into the extracellular space and peripheral circulation [10]. The role 
of extracellular HSPs has not been precisely determined so far. It has been shown, however, 
that circulating HSPs and/or anti-HSP antibodies can be useful carcinogenesis biomarkers, as 
well as prognostic factors affecting treatment outcomes [11]. The presence of HSPs in the 
serum of ovarian cancer patients is still a new area of study. It is necessary to continue studies 
on possibilities for using these markers to predict a patient’s response to a specific therapy 
and to monitor treatment progress. 
The aim of this study was, therefore, the evaluation of serum HSP27 levels in ovarian 
cancer patients in FIGO clinical stages I–IV according to histopathological type. 
 
MATERIAL AND METHODS 
The study included 52 women with ovarian cancer, hospitalised at the Department of 
Obstetrics, Gynaecology and Oncological Gynaecology, Medical University of Silesia. 
Patients with cardiovascular disease, diabetes mellitus, autoimmune diseases, etc. were 
excluded from the study. Twenty-five healthy women, of comparable age, were included in 
the control group. 
Blood samples (ca. 5 mL vol.) were collected in the morning from antecubital veins. 
The sera obtained were stored at –70oC until required for assays.  
The Local Bioethics Committee of the Silesian Medical University approved the study 
protocol. All patients enrolled in the study were explained the study protocol and gave written 
informed consent to their participation. 
The levels of the HSP27 in the studied sera were determined by an immunoenzymatic 
method (ELISA), using HSP27 (human) ELISA kits from Enzo Life Sciences (Farmingdale, 
NY, USA). The assay conditions and the procedure were in accordance with the 
manufacturer’s recommendations. Determinations were conducted in duplicate, in one series. 
The obtained results were subjected to statistical analysis. Normal distribution of the 
data was checked with the Shapiro-Wilk test. The groups were compared using the 
Kolmogorov-Smirnov test, the Mann-Whitney U-test, and the test of differences between 
structure indexes. For variability testing in the group of patients with ovarian cancer, the 
Kruskal-Wallis rank ANOVA test was used. Spearman’s rank test was used for correlations. 
A p-value less than 0.05 was considered statistically significant. Calculations were performed 
with STATISTICA for Windows 10.0.  
 
RESULTS 
The mean age of women with ovarian cancer and healthy controls was comparable 
(55.8 ± 10.1 vs 53.1 ± 7.2 years). Of the 52 studied patients, ovarian cancer was diagnosed in 
27 for the first time, i.e., they had not received any oncological treatment, while 25 patients 
had already undergone previous treatment with chemotherapy. Patients with clinical stage 
according to FIGO I–IV and with different histopathological forms of the tumour were 
recruited to the studied group (Tab. 1).  
Table 2 presents the mean levels of HSP27 in both groups. The mean concentration of 
HSP27 in those patients with ovarian cancer was significantly higher than in the control group 
(p = 0.005). Positive results (values exceeding the mean + 2 SD for the control group) were 
recorded in 42% of patients with ovarian cancer, and this ratio was significantly higher than in 
the control group. 
The analysis of the mean levels of HSP27 in the patients with ovarian cancer, versus 
clinical stage of disease (FIGO), showed that these levels increased with the neoplastic 
process progress (Tab. 3). The mean HSP27 levels in patients at clinical stages II, III and IV 
were significantly higher than at stage I (p = 0.049, p = 0.038 and p = 0.0038, respectively) 
and in the control group (p = 0.018, p = 0.015 and p = 0.0005, respectively). The mean HSP27 
levels in patients at stage IV was higher than at stages II (p = 0.009) and III (p = 0.015). 
Positivity values analysis revealed in all clinical stages of ovarian cancer, excluding stage I, it 
was significantly higher than in the control group, and at the IV stage, it is significantly higher 
than at the I, II, and III stages (p = 0.027, p = 0.039 and p = 0.0183, respectively) (Tab. 3). 
The mean levels of HSP27 in the patients with ovarian cancer did not differ 
significantly depending on the cancer’s histopathological type. In patients with 
adenocarcinoma papillare serosum and with adenocarcinoma endometrioides, the mean 
levels of this protein remained significantly higher compared to the control group (p = 0.004 
and p = 0.05, respectively), while in patients with adenocarcinoma mucinosum it was 
comparable to that observed in the control group (p = 0.48) (Tab. 4). The positive value ratios 
for individual histopathological types of ovarian cancer were also comparable, and for 
adenocarcinoma papillare serosum and adenocarcinoma endometrioides significantly higher 
compared to the control group.  
Use of primary chemotherapy did not result in a reduction in HSP27 levels, as the 
mean levels of this protein did not differ significantly between the group of patients 
previously subjected to anticancer treatment and the untreated group. The positive value ratios 
were also comparable in both groups of patients (Tab. 5). However, both in untreated patients 
and in patients after chemotherapy, the mean HSP27 levels were higher than in the healthy 
controls (p = 0.038 and p = 0.0062, respectively). A similar relationship was found for the 
positive value ratios. 
In both studied groups of women – ovarian cancer patients and the control group of 
healthy women – HSP27 levels were not correlated with age (p = 0.52, R = 0.09 and p = 0.84, 
R = 0.04, respectively).  
 
DISCUSSION 
Heat shock proteins are excessively expressed in many human malignant neoplasms. 
They participate in the proliferation of tumour cells, modify their growth, differentiation, and 
affect the occurrence of metastasis and modulate their death and recognition by the immune 
system [11, 12]. Some authors have pointed out that increased HSP activity is associated with 
poor prognosis in certain types of cancer, including ovarian cancer, and results in poorer 
response to treatment [12, 13]. This raises the question of why HSP proteins change their 
activity in cancer cells. This may be due to reduced glucose levels, hypoxia, and pH changes 
within the tumour. It may also be due to genetic changes associated with malignant 
transformation [14, 15]. As mentioned above, HSPs play a role in apoptosis and show 
increased expression in cancer cells. Since cancer cells can be resistant to proapoptotic 
signals, HSP proteins are currently being investigated as potential therapeutic targets and 
diagnostic markers in cancer [16]. 
The heat shock protein possibly engaged in the carcinogenesis process is HSP27. This 
protein is excessively expressed in malignantly transformed endometrium [17] and is 
considered a marker for cervical squamous metaplasia [18]. Increased HSP27 expression was 
found in neoplastic tissue in the lungs, urinary bladder, kidneys, breast, oesophagus, liver, 
various cancers of the central nervous system and melanomas [19]. Anti-HSP27 antibodies 
were also found in women with endometrial, cervical, vaginal and vulvar cancers [20]. 
Studies on HSP27 expression in ovarian cancer are still scarce. It was shown that malignant 
ovarian cancers are characterised by significantly higher HSP27 levels in tumour tissues, 
versus a non-malignant neoplasm of that organ and untransformed ovarian cells [21]. It was 
also found that HSP27 expression in ovarian tumours increases with the neoplasm stage and is 
significantly higher in ovarian epithelial cancers with metastases to the peritoneum, versus 
tumours without such metastases [22]. In women with ovarian cancer, serum anti-HSP27 IgG 
antibody levels are significantly higher than in healthy women [20, 23], and in specimens 
sampled from the cervix of women with ovarian cancer, anti-HSP27 IgA was found in almost 
80% of cases [24]. The mechanism for producing antibodies against heat shock proteins in 
patients with a neoplasm is unclear, but the appearance of such antibodies suggests that during 
the malignant process its corresponding antigen (HSP27), a typical intracellular protein, is 
available in its extracellular form [25]. In nearly 40% of ovarian cancer patients, free HSP27, 
and HSP27-cytochrom c complexes in nearly 30% of these, can be found in specimens 
collected from the cervix (but only in 10% of patients with non-malignant lesions in the 
genital tract) [26]. Very little is known about the HSP27 levels in women with ovarian cancer, 
whereas increased values have already been found in the serum of patients with breast cancer 
[27] or pancreatic cancer [28]. In this last case, it has even been suggested that HSP27 
(determined in the serum by ELISA) could be used as a new biomarker for early diagnosis of 
this neoplasm. In the studied group of women with ovarian cancer, the mean serum HSP27 
level was significantly higher than in the control group, and in over 40% of cases reached 
values considered as positive. The mechanism for the release of heat shock proteins, including 
HSP27, into the extracellular space and circulation remains unknown. One of the possibilities 
is the transport of cytoplasmic HSPs together with other proteins containing transmembrane 
domains [29] or a direct HSP interaction with cellular membrane phospholipids [30]. Another 
possibility is HSP release from necrotic tumour cells [31]. The role of extracellular heat shock 
proteins in the pathogenesis of the malignant process is also not fully known. Extracellular 
HSP90 is considered to play a particularly significant role in neoplastic invasion (neoplastic 
cell angiogenesis, mobility and migration, formation of metastases) [32, 33]. It seems that 
tumour cells are characterised by constitutive secretion of this protein, enabling them to 
invade tissues [34]. It is known that extracellular HSP27 acts as an anti-inflammatory 
stimulus inducing Il-10 production by monocytes, and this may facilitate inhibition of TNF-
alpha dependant apoptosis [35]. On the other hand, the immunogenic properties of 
extracellular HSPs may contribute to the development of the specific anticancer 
immunological response [36].  
A very important issue is HSP27 expression during development of the neoplastic 
process, i.e., a study of the relationship between HSP27 levels and the disease’s clinical 
progress. In other studies [37, 38], the more advanced the clinical stage (FIGO) of the disease, 
the lower the HSP27 expression (assessed by an immunohistochemical method) in the tumour 
tissues. Also, in the studies of Elpek et al., [39], HSP27 expression in tumour tissues was 
positively correlated with the cancer’s FIGO clinical stage. Little is known, however, about 
the relationship between the clinical stage of ovarian cancer and the HSP27 levels in the 
serum. In the studied group of patients, the more advanced the disease’s clinical stage, the 
higher the mean HSP27 levels in the patients’ serum. Furthermore, in patients at clinical stage 
I, only 13% positive results were recorded, while in patients at stage IV, it was as much as 
88%. These observations may indicate increasing extracellular HSP27 expression during 
development of the malignant process. Increased circulating levels may reflect an increase in 
the active secretion of this protein into the extracellular space accompanying an increasing 
tumour mass or simultaneous intensified necrotic processes during cancer development and, 
thus, increased HSP27 release from damaged cells. 
 Heat shock protein expression may be modified according to the degree of tumour 
tissue differentiation. HSP27 expression seems to be related to higher malignant cell 
differentiation in endometrial cancers [40] and squamous cancers (uterine cervix, oral 
epithelium) [18, 41], whereas in malignant astrocytomas/glioblastomas, on the contrary, there 
is lower cell differentiation [42]. This expression can also differ in histopathologically 
different tumours of the same organ. For example, in oesophageal cancers, HSP27 expression 
is reduced during carcinogenesis leading to adenocarcinoma [43] but increases during the 
development of squamous-cell carcinoma [44]. In the case of ovarian cancers, no significant 
differences were observed for HSP27 expression intensity and the histopathological cancer 
subtype in that organ [37]. In the studied group of ovarian cancer patients, mean serum 
HSP27 levels also did not differ significantly depending on the histopathological subtype of 
this cancer, similarly to the positive value ratios. This analysis disclosed, however, that in 
those patients with adenocarcinoma mucinosum, these levels were significantly lower and did 
not differ (similarly to the positive values ratio) from those observed in the control group. 
This may result from the fact that most mucinous ovarian tumours are diagnosed when they 
are low-grade (or borderline) and at an early stage. 
HSP27’s contribution to the development of tumour resistance to treatment, 
particularly to chemotherapy, is quite widely discussed. Excessive HSP27 expression is 
associated with the chemoresistance of breast tumours, head and neck cancers, oesophageal 
squamous-cell carcinoma and leukaemia [45]. It has been shown that in women with ovarian 
cancer, increased HSP27 activity can lead to resistance to chemotherapy [4], and after 
treatment it is not reduced significantly. Using an immunohistochemical method, it was 
observed that HSP27 expression is increased in 86% of cases before and in as many as 72% of 
cases after treatment with doxorubicin and cisplatin [46]. HSP27 overproduction also 
characterised cisplatin-resistant ovarian cancer cell lines in culture [47], while cytostatic drugs 
increased the activity of this protein in ovarian cancer cells [48]. The involvement of HSP 
proteins in the development of resistance of cancer tumours to chemotherapy is not fully 
known. HSP27 is a protective protein and thus likely has cytoprotective effects on cancer cells 
by "repairing" proteins that have been damaged by anti-cancer drugs [45, 49]. However, most 
authors believe that the main mechanism of action of HSPs is to protect cancer cells from 
apoptosis. HSPs present in increased quantities react with the components of apoptotic 
pathways and, in consequence, promote the survival of cancer cells, additionally protecting 
them against mitochondrial damage [50]. HSP27 has been found to have a protective effect on 
cells against reactive oxygen species initiated by, among others, by TNF-, which, depending 
on the level, may cause cellular apoptosis or necrosis [51]. Finally, HSP27 may protect the 
tumour microvasculature, as its presence is also found in vascular endothelial cells [52]. Our 
observations correspond to the results of the authors quoted above, as the mean levels of 
HSP27 in patients after chemotherapy and before treatment do not differ, with the positive 
value ratios also not differing. Thus, it can be concluded that the use of chemotherapy as an 
initial anticancer treatment does not affect extracellular HSP27 expression, or it only modifies 
its mechanism, e.g., from active secretion to release from necrotic cells. This issue, however, 
requires further studies to explain it. 
HSP27 is also a candidate for an independent factor for deciding on the prognosis in 
some cancer types. Data on the relationship between HSP27 expression in tumour tissues and 
the prognosis and survival in ovarian cancers are contradictory. Most authors indicate a 
relationship between HSP27 expression and poorer survival prognosis [39, 53], however, 
there is data suggesting that intracellular expression of this protein can be a marker for longer 
survival [54, 55]. There is no data on a possible role for extracellular HSP27 as a prognostic 
marker for survival in ovarian cancer.  
HSPs, including HSP27, can have different functions depending on their location: 
intracellular – cytoprotective, and extracellular – immunogenic [16, 29]. From the point of 
view of development of the malignant process, this may be perceived as a paradox. On one 
hand, these proteins can, after cell transformation, facilitate neoplasm malignancy and its 
resistance to treatment. On the other hand, their extracellular forms may have a positive role 
in the development of a specific anticancer immunological response. Studies on the role of 
extracellular HSP27 in the development of the neoplastic process in cancer are still scarce. 
Our data indicates that expression of this form accompanies the development of epithelial 
ovarian cancers and increases with the advancing clinical stages of the cancer. The question 
about the role of this form in the development of the malignant phenotype and/or the host’s 
anticancer response remains unanswered. Should it be the target for the therapy or is there 
support from an advantageous agent in fighting the cancer? Our studies indicate a significant 
contribution of HSP27 to the pathogenesis of ovarian cancer. It seems that serum HSP27 can 
be a marker for this cancer’s development, and a marker of its clinical stage. However, as this 
protein can also be present in the serum of healthy people [56], it is necessary to establish the 
threshold level for a cut-off point which allows differentiation between the correct status and 
the disease when using sensitive quantitative techniques. The ELISA technique is good one 
for the quantitative assessment of serum HSP27 levels. Although diagnostic HSP27 levels 
have not yet been precisely specified, we can conclude the usefulness of this marker for 





Table 1. Summary of clinical characteristics of the study group (n = 52) 
Clinical details No (%) 
Anti-cancer therapy 
 untreated so far 27 (51.9) 
 after primary chemotherapy 25 (48.1) 
Histopathological type: 
 adenocarcinoma papillare serosum 33 (63.5) 
 adenocarcinoma mucinosum 8 (15.4) 
 adenocarcinoma endometrioides 11 (21.1) 
Clinical stage (FIGO): 
 I 8 (15.4) 
 II 12 (23.1) 
 III 24 (46.1) 









n = 52 
Controls  
n = 25 
Hsp27 (ng/mL)  
(mean ± SD) 
50.17 ± 57.59* 13.65 ± 11.62 
% of positive results 
(> mean + 2SDs for control group) 
42%* 
4% 
p = 0.0006 
SD — standard deviation 
* p < 0.05 ovarian cancer vs controls 
 
  




Clinical stage (FIGO)  
Controls 
n = 25 
I 
n = 8 
II 
n = 12 
III 
n = 24 
IV 
n = 8 
Hsp27 (ng/mL) 
(mean ± SD) 
13.41a) b) c) 
± 17.65 
36.41 d) f)  
± 30.62 






% of positive 
results 
(> mean + 2SDs for 
control group) 
13% 42% f) 38% f) 88% f) g) 
4% 
p = 0.3576 p = 0.0034 p = 0.0033 p = 0.0000 
SD — standard deviation 
a) p < 0.05 I vs II; b) p < 0.05 I vs III; c) p < 0.05 I vs IV; d) p < 0.05 II vs IV; e) p < 0.05 III vs 





Table 4. Concentrations of Hsp27 in study group depending on histopathological type of 





n = 25 
adenocarcinoma 
papillare serosum 
n = 33 
adenocarcinoma 
mucinosum 
n = 8 
adenocarcinoma 
endometrioides 
n = 11 
Hsp27 (ng/mL) 
(mean ± SD) 
40.27* ± 59.45 26.72 ± 31.45 44.79* ± 50.81 
13.65  
± 11.62 
% of positive 
results 
(> mean + 2SDs for 
control group) 
42%* 25% 45%* 
4% 
p = 0.001 p = 0.072 p = 0.0023 
SD — standard deviation 




Table 5. Concentrations of Hsp27 in group of women with ovarian cancer depending on 




Phase of antineoplastic treatment 
Controls 
n = 25 untreated so far 
n = 27 
after chemotherapy 
n = 25 
Hsp27 (ng/mL) 
(mean ± SD) 
53.37* ± 55.54 46.72* ± 60.68 
13.65  
± 11.62 
% of positive results 




p = 0.0003 p = 0.0047 
SD — standard deviation 
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